NCT06698432 (SHR-CMD-CCS) is a clinical trial of caIMR in Coronary Microvascular Dysfunction (CMD), sponsored by Ya-Wei Xu.

Who is sponsoring NCT06698432?

NCT06698432 is sponsored by Ya-Wei Xu.

What drugs are being tested in NCT06698432?

Interventions in NCT06698432: caIMR.

What condition does NCT06698432 study?

NCT06698432 studies Coronary Microvascular Dysfunction (CMD), Index of Microvascular Resistance, Chronic Coronary Syndrome, Prognosis.

Is NCT06698432 still recruiting?

NCT06698432 is currently completed. Last updated 21 November 2024.

Last reviewed 2024-11-21 · How we verify

NCT06698432: SHR-CMD-CCS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SHR Predicts CMD in Patients with CCS

Completed Last updated 21 November 2024

What this trial tests

trial testing caIMR in Coronary Microvascular Dysfunction (CMD) in 379 participants. Completed in 1 June 2019.

Timeline

1 June 2015

Primary endpoint
1 June 2019

1 June 2019

Quick facts

Lead sponsor	Ya-Wei Xu
Status	Completed
Study type	OBSERVATIONAL
Enrollment	379
Start date	1 June 2015
Primary completion	1 June 2019
Estimated completion	1 June 2019

Drugs / interventions tested

caIMR

Conditions studied

Coronary Microvascular Dysfunction (CMD) — all drugs for Coronary Microvascular Dysfunction (CMD) →
Index of Microvascular Resistance — all drugs for Index of Microvascular Resistance →
Chronic Coronary Syndrome — all drugs for Chronic Coronary Syndrome →
Prognosis — all drugs for Prognosis →

Sponsor

Ya-Wei Xu — full company profile →

Who can join

18 and older, any sex, with Coronary Microvascular Dysfunction (CMD) or Index of Microvascular Resistance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SHR exerts a significant influence in numerous cardiovascular diseases, including MINOCA (myocardial infarction with non - obstructive coronary arteries), HFpEF (heart failure with preserved ejection fraction), and CAD (coronary artery disease). It thereby demonstrates its predictive capacity regarding survival risk and its value in risk-stratification procedures. To date, no studies have specifically investigated the prognostic implications of the stress hyperglycemia ratio (SHR) in CMD patients with CCS, highlighting the need for further research. Therefore, this study seeks to evaluate the predictive value of the stress hyperglycemia ratio (SHR) in CMD patients with CCS, and to elucidate its clinical relevance and significance, which remain poorly understood in this patient cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of caIMR

Trials testing the same drug.

NCT06945094 — A Multi-center, Real-World Clinical Trial of caIMR on Two Specific Kinds of Patients. · not yet recruiting
NCT06190704 — Prognostic Significance of CMD Assessed by IMR in HCM Patients · completed

Other recruiting trials for Coronary Microvascular Dysfunction (CMD)

Currently open trials in the same condition.

NCT06681896 — Microvascular Coronary Rehabilitation For Improving Treatment - Feasibility Study · NA · recruiting
NCT06588244 — INOCA-NA a Local Prospective Registry · recruiting
NCT04674449 — iCorMicA - Stratified Medicine in Angina · NA · recruiting
NCT06702748 — Prognostic Values of Coronary Microvascular Dysfunction Patients Treated with Rotational Atherectomy During Percutaneous · active not recruiting

Other Ya-Wei Xu trials

Trials by the same sponsor.

NCT06690684 — Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases · enrolling by invitation
NCT05935436 — Cardiac Shock Wave Therapy for the Treatment of Myocardial Infarction With Non-obstructive Coronary Arteries · NA · unknown
NCT05354128 — Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak. · NA · unknown
NCT06385782 — Exploring HRV in Antarctic Overwintering Members of Asia · completed
NCT03802929 — Diagnostic and Prognostic Prediction Models for Chinese Patients With Venous Thromboembolism · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06698432 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ya-Wei Xu
Last refreshed: 21 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06698432.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing